+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Hollingsworth & Vose Co - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 22 Pages
  • June 2026
  • GlobalData
  • ID: 5367407
Hollingsworth & Vose Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Hollingsworth & Vose Co (H&V) is a supplier of supply of advanced materials for filtration, battery separator, and industrial applications. The company offers a range of filtration media, battery separators, and several industrial products to various industries such as transportation, indoor air quality, industrial and manufacturing, heavy equipment, energy generation and storage, apparel and home furnishings, and aerospace. It offers its products under various brands such as AGM EnergyGuard, PowerLock, NanoWave, Nanoweb, AlphaPerm, Technostat, and Trupor. H&V operates manufacturing sites and research and development centers in the Americas, Asia and Europe. H&V is headquartered in East Walpole, Massachusetts, the US.

Hollingsworth & Vose Co Key Recent Developments

  • May 04, 2026: Hollingsworth & Vose Wins 2026 BCI Innovation Award

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Karyopharm Therapeutics Inc - Key Facts
  • Karyopharm Therapeutics Inc - Key Employees
  • Karyopharm Therapeutics Inc - Key Employee Biographies
  • Karyopharm Therapeutics Inc - Major Products and Services
  • Karyopharm Therapeutics Inc - History
  • Karyopharm Therapeutics Inc - Company Statement
  • Karyopharm Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Karyopharm Therapeutics Inc - Business Description
  • Other Break-up: License and Other Revenue
  • Performance
  • Other Break-up: Product Revenue, Net
  • Performance
  • R&D Overview
  • Karyopharm Therapeutics Inc - Corporate Strategy
  • Karyopharm Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Karyopharm Therapeutics Inc - Strengths
  • Karyopharm Therapeutics Inc - Weaknesses
  • Karyopharm Therapeutics Inc - Opportunities
  • Karyopharm Therapeutics Inc - Threats
  • Karyopharm Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Karyopharm Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 14, 2026: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
  • Mar 24, 2026: Karyopharm Announces $30 Million Private Placement With RA Capital
  • Feb 12, 2026: Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
  • Jan 12, 2026: Karyopharm Reports Preliminary Unaudited 2025 Revenue and Expects Phase 3 Data in 2026
  • Jan 02, 2026: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
  • Dec 08, 2025: Karyopharm to Participate in Baird's Biotech Discovery Series
  • Dec 01, 2025: Karyopharm to Participate in Piper Sandler 37th Annual Healthcare Conference
  • May 12, 2025: Karyopharm Therapeutics Announces Q1 2025 Results
  • May 12, 2025: Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
  • Feb 19, 2025: Karyopharm Therapeutics Posts Results for Q4 and Full Year Ended December 31, 2024
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Karyopharm Therapeutics Inc, Key Facts
  • Karyopharm Therapeutics Inc, Key Employees
  • Karyopharm Therapeutics Inc, Key Employee Biographies
  • Karyopharm Therapeutics Inc, Major Products and Services
  • Karyopharm Therapeutics Inc, History
  • Karyopharm Therapeutics Inc, Subsidiaries
  • Karyopharm Therapeutics Inc, Key Competitors
  • Karyopharm Therapeutics Inc, Ratios based on current share price
  • Karyopharm Therapeutics Inc, Annual Ratios
  • Karyopharm Therapeutics Inc, Interim Ratios
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Karyopharm Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Karyopharm Therapeutics Inc, Performance Chart (2021 - 2025)
  • Karyopharm Therapeutics Inc, Ratio Charts
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026